These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 24016390)
1. Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. Lafeuille MH; Laliberté-Auger F; Lefebvre P; Frois C; Fastenau J; Duh MS BMC Psychiatry; 2013 Sep; 13():221. PubMed ID: 24016390 [TBL] [Abstract][Full Text] [Related]
2. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge. Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223 [TBL] [Abstract][Full Text] [Related]
3. Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database. Voss EA; Ryan PB; Stang PE; Hough D; Alphs L Int Clin Psychopharmacol; 2015 May; 30(3):151-7. PubMed ID: 25730525 [TBL] [Abstract][Full Text] [Related]
4. Risperidone long-acting injection and 1-year rehospitalization rate of schizophrenia patients: A retrospective cohort study. Chan HW; Huang CY; Feng WJ; Yen YC Psychiatry Clin Neurosci; 2015 Aug; 69(8):497-503. PubMed ID: 25781185 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain. Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A; Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869 [TBL] [Abstract][Full Text] [Related]
6. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation]. Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I Encephale; 2005; 31(2):235-46. PubMed ID: 15959450 [TBL] [Abstract][Full Text] [Related]
7. Drug Utilization of Japanese Patients Diagnosed with Schizophrenia: An Administrative Database Analysis. Cheung S; Hamuro Y; Mahlich J; Nakahara T; Sruamsiri R; Tsukazawa S Clin Drug Investig; 2017 Jun; 37(6):559-569. PubMed ID: 28361438 [TBL] [Abstract][Full Text] [Related]
8. Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy. Alphs L; Nasrallah HA; Bossie CA; Fu DJ; Gopal S; Hough D; Turkoz I Int Clin Psychopharmacol; 2016 Jul; 31(4):202-9. PubMed ID: 26974214 [TBL] [Abstract][Full Text] [Related]
9. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics. Shah A; Xie L; Kariburyo F; Zhang Q; Gore M Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study. Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986 [TBL] [Abstract][Full Text] [Related]
12. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics. Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292 [TBL] [Abstract][Full Text] [Related]
13. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia. Song X; El Khoury AC; Brouillette M; Smith D; Joshi K J Med Econ; 2019 Nov; 22(11):1105-1112. PubMed ID: 31062998 [No Abstract] [Full Text] [Related]
14. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable. Rosa F; Schreiner A; Thomas P; Sherif T Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430 [TBL] [Abstract][Full Text] [Related]
15. Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia. Lafeuille MH; Dean J; Carter V; Duh MS; Fastenau J; Dirani R; Lefebvre P Curr Med Res Opin; 2014 Aug; 30(8):1643-55. PubMed ID: 24730586 [TBL] [Abstract][Full Text] [Related]
16. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596 [TBL] [Abstract][Full Text] [Related]
17. Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics. Lin CH; Chen FC; Chan HY; Hsu CC Int J Neuropsychopharmacol; 2019 Sep; 22(9):541-547. PubMed ID: 31260538 [TBL] [Abstract][Full Text] [Related]
18. Combination Antipsychotic Therapies: An Analysis From a Longitudinal Pragmatic Trial. Foster A; Buckley P; Lauriello J; Looney S; Schooler N J Clin Psychopharmacol; 2017 Oct; 37(5):595-599. PubMed ID: 28806390 [TBL] [Abstract][Full Text] [Related]
19. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Lauriello J; McEvoy JP; Rodriguez S; Bossie CA; Lasser RA Schizophr Res; 2005 Jan; 72(2-3):249-58. PubMed ID: 15560969 [TBL] [Abstract][Full Text] [Related]
20. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. Offord S; Wong B; Mirski D; Baker RA; Lin J J Med Econ; 2013; 16(2):231-9. PubMed ID: 23163287 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]